Belite Bio, Inc(BLTE)Earnings, Financials & Key Ratios
BLTE•NASDAQ
$157.69
Price updated Jul 7, 2026
AboutBelite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.Show more
- Revenue$0
- EBITDA-$84M-111.8%
- Net Income-$78M-114.7%
- EPS (Diluted)-2.31-95.8%
- ROE-16.94%+44.6%
BLTE Price & Volume
Belite Bio, Inc (BLTE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Significant Cash Burn
Investment Thesis • Updated 2025Q4
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Binary clinical trial outcomes
Key Thesis Takeaways
- Belite Bio remains in a high-stakes, pre-revenue clinical phase, with its valuation tethered to the successful execution of Phase 3 trials for its lead assets.
- While the company has successfully bolstered its balance sheet to $780.6 million in total assets, the rapid escalation of quarterly R&D expenses to $14.6 million suggests a narrowing window for clinical success.
- Investors should monitor the sustainability of this cash runway, as the current net loss of $25.3 million per quarter may necessitate further dilutive financing if trial timelines extend beyond current projections.
Verdict Logic
while the $352.9 million cash position provides near-term stability, the lack of commercial revenue and the $25.3 million quarterly net loss create significant binary risk for long-term shareholders.
BLTE Growth Metrics
Belite Bio, Inc (BLTE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-99.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-78.38%
Return on Capital
10 Years-35.61%
5 Years-38.09%
3 Years-33.22%
Last Year-18.37%
BLTE Recent Earnings
Belite Bio, Inc (BLTE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.34+43.3%
$0.60
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.38+32.1%
$0.56
Rev
—
$17M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.65-22.6%
$0.53
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.50-6.4%
$0.47
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.34vs $0.60+43.3% | — |
| Q2 2026 | Mar 2, 2026 | $0.38vs $0.56+32.1% | —vs $17M |
| Q4 2025 | Nov 10, 2025 | $0.65vs $0.53-22.6% | — |
| Q3 2025 | Aug 11, 2025 | $0.50vs $0.47-6.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Belite Bio, Inc (BLTE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $157.69 | $6.32B | -68.26 | — | — | -16.94% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $11.51 | $966.21M | -3.41 | — | — | -128.57% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Compare BLTE vs Peers
Belite Bio, Inc (BLTE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BLTE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BLTE Frequently Asked Questions
Belite Bio, Inc (BLTE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BLTE profitable?
Belite Bio, Inc (BLTE) reported a net loss of $66.0M for fiscal year 2025.
Dividend & Returns
What is BLTE's return on equity?
Belite Bio, Inc (BLTE) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
What is Belite Bio, Inc's free cash flow?
Belite Bio, Inc (BLTE) had negative free cash flow of $0.0M in fiscal year 2025, likely due to heavy capital investments.